

PMCF Study need Assessment

| | |
|--|--|
| Device Information | |
| Product Name | |
| Description of the Device (short; focus on technical specifications) | |
| Device class and classification rationale | |
| Intended purpose | |
| Contraindications | |
| Basic UDI-DI | |
| FDA code and/or other applicable codes (e.g. MDA/MDN codes) | |

| | |
|--|---------|
| Novelty | |
| The design of the device, the materials, substances, principles of operation, technology, or medical indications are novel | |
| Justification | Applies |
| | |

| | |
|-------------------------------------|---------|
| Equivalence | |
| CE marking was based on equivalence | |
| Response | Applies |
| | |

| | |
|---|---------|
| Inherent Risks/ Intended Population | |
| <ul style="list-style-type: none"> High risk with respect to the intended population and/or a subgroup (e.g. elderly, pediatrics, patients with as specific comorbidity etc.) Identification of previously unstudied subpopulations which may be impacting the different benefit/risk-ratio of the device Difficulty to generalize the clinical outcomes of available clinical investigations. | |
| Justification | Applies |
| | |

| | |
|--|---------|
| Significant Design Changes | |
| There is a significant change to the device that has resulted or is expected to result in the revision of its original intended purpose. | |
| Justification | Applies |
| | |

| | |
|---|---------|
| High Risk due to Anatomical Location | |
| The intended use is in a high-risk location, e.g. CNS | |
| Justification | Applies |
| | |
| | |

| | |
|---|---------|
| High Risk due to Product Specifications | |
| There is a high product risk based on design, materials, components, invasiveness, or clinical procedures | |
| Justification | Applies |
| | |

| | |
|--|---------|
| Unsubstantiated Indications | |
| The device's indications for use are not sufficiently supported with existing clinical evidence. | |
| Justification | Applies |
| | |

| | |
|--|---------|
| Unsubstantiated Claims | |
| Clinical claims on clinical safety and performance are not sufficiently supported with existing clinical evidence. | |
| Justification | Applies |
| | |

| | |
|--|---------|
| Long-term Safety and Performance | |
| <ul style="list-style-type: none"> Emergence of new data (e.g. from vigilance databases) on safety and/or performance of the target device and/or similar devices. Consider any unaddressed CAPAs herein | |
| Justification | Applies |
| | |

| | |
|--|---------|
| Risk Reduction | |
| Is there sufficient evidence to support the continued acceptability of the benefit-risk ratio of the device? | |
| Justification | Applies |
| | |

| | |
|---|---------|
| Expected Intended Lifetime | |
| <ul style="list-style-type: none"> Unanswered questions on the long-term safety and performance of the target device. Currently available clinical investigations do not cover the whole range of the intended lifetime of the target device. | |
| Justification | Applies |
| | |

| | |
|---|---------|
| Insufficient/Incomplete previous Clinical Investigations | |
| There are unaddressed issues with respect to results of previous clinical investigation(s) including adverse events | |
| Justification | Applies |
| | |

| | |
|--|---------|
| Risk profile of similar medical devices | |
| <ul style="list-style-type: none"> Emergent risks identified in the literature for similar devices in the same intended medical field New information on safety or performance of the target device and/or similar emerges from the literature | |
| Justification | Applies |
| | |

| | |
|---|---------|
| Health Economics/ Reimbursement /Market Access | |
| Clinical evidence is necessary to support market access and/or continued market acceptance. | |
| Justification | Applies |
| | |